07/07/2025
Across England, access to Tirzepatide (also called Mounjaro®) medication is being phased and prioritised to ensure patients with the greatest clinical need can receive it.
Cohort 1 – will start in the summer of 2025 in response to the requirement of NICE to make this drug available in “Primary Care Settings”. GPs should not directly prescribe tirzepatide for weight loss. The ICB is in the process of commissioning community/primary care weight loss prescribing services so that GPs have somewhere to refer eligible patients in line with the NICA TA1026 and NHS England Commissioning Guidance. As soon as these are available we will update you, we are looking to implement these as soon as possible.
The FAQs describe eligibility but for clarity the national roll out set by NHS England mean access this year is only for people with at least 4 of the 5 health conditions listed below plus a BMI of at least 40 (BMI to be adjusted for ethnicity*).
The following weight-related health conditions will be used to define those who are eligible first:
- type 2 diabetes mellitus
- high blood pressure
- heart disease
- obstructive sleep apnoea (when your breathing stops and starts -while you sleep)
- abnormal blood fats (dyslipidaemia)
See below here for more information.
Tirzepatide (Mounjaro®) for the management of obesity Semaglutide (Wegovy®) for the management of obesity Tirzepatide (Mounjaro®) for the management of obesity National Institute for Health and Care Excellence (NICE) recommends tirzepatide (Mounjaro®) for the management of obesity for certain pa...